Literature DB >> 32060212

Intraoperative 68Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study.

Christopher Darr1, Nina N Harke2, Jan Philipp Radtke2, Leubet Yirga2, Claudia Kesch2, Maarten R Grootendorst3, Wolfgang P Fendler4, Pedro Fragoso Costa4, Christoph Rischpler4, Christine Praus4, Johannes Haubold5, Henning Reis6, Thomas Hager6, Ken Herrmann4, Ina Binse4, Boris Hadaschik2.   

Abstract

Our objective was to assess the feasibility and accuracy of Cerenkov luminescence imaging (CLI) for assessment of surgical margins intraoperatively during radical prostatectomy.
Methods: A single-center feasibility study included 10 patients with high-risk primary prostate cancer (PC). 68Ga-prostate-specific membrane antigen (PSMA) PET/CT scans were performed followed by radical prostatectomy and intraoperative CLI of the excised prostate. In addition to imaging the intact prostate, in the first 2 patients the prostate gland was incised and imaged with CLI to visualize the primary tumor. We compared the tumor margin status on CLI to postoperative histopathology. Measured CLI intensities were determined as tumor-to-background ratio.
Results: Tumor cells were successfully detected on the incised prostate CLI images as confirmed by histopathology. Three of 10 men had histopathologically positive surgical margins (PSMs), and 2 of 3 PSMs were accurately detected on CLI. Overall, 25 (72%) of 35 regions of interest proved to visualize a tumor signal according to standard histopathology. The median tumor radiance in these areas was 11,301 photons/s/cm2/sr (range, 3,328-25,428 photons/s/cm2/sr), and median tumor-to-background ratio was 4.2 (range, 2.1-11.6). False-positive signals were seen mainly at the prostate base, with PC cells overlaid by benign tissue. PSMA immunohistochemistry revealed strong PSMA staining of benign gland tissue, which impacts measured activities.
Conclusion: This feasibility showed that 68Ga-PSMA CLI is a new intraoperative imaging technique capable of imaging the entire specimen's surface to detect PC tissue at the resection margin. Further optimization of the CLI protocol, or the use of lower-energy imaging tracers such as 18F-PSMA, is required to reduce false-positives. A larger study will be performed to assess diagnostic performance.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  Cerenkov luminescence imaging; margin assessment; prostate cancer; radical prostatectomy; radioguided surgery

Mesh:

Substances:

Year:  2020        PMID: 32060212      PMCID: PMC7539648          DOI: 10.2967/jnumed.119.240424

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  35 in total

1.  Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients.

Authors:  Thorsten Schlomm; Pierre Tennstedt; Caroline Huxhold; Thomas Steuber; Georg Salomon; Uwe Michl; Hans Heinzer; Jens Hansen; Lars Budäus; Stefan Steurer; Corinna Wittmer; Sarah Minner; Alexander Haese; Guido Sauter; Markus Graefen; Hartwig Huland
Journal:  Eur Urol       Date:  2012-05-10       Impact factor: 20.096

2.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

3.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

4.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

Authors:  Marlon Perera; Nathan Papa; Matthew Roberts; Michael Williams; Cristian Udovicich; Ian Vela; Daniel Christidis; Damien Bolton; Michael S Hofman; Nathan Lawrentschuk; Declan G Murphy
Journal:  Eur Urol       Date:  2019-02-14       Impact factor: 20.096

5.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Authors:  Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

6.  The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Authors:  Lorenzo Bianchi; Alessandro Nini; Marco Bianchi; Giorgio Gandaglia; Nicola Fossati; Nazareno Suardi; Marco Moschini; Paolo Dell'Oglio; Riccardo Schiavina; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2015-12-31       Impact factor: 20.096

7.  68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

Authors:  Annika Herlemann; Vera Wenter; Alexander Kretschmer; Kolja M Thierfelder; Peter Bartenstein; Claudius Faber; Franz-Josef Gildehaus; Christian G Stief; Christian Gratzke; Wolfgang P Fendler
Journal:  Eur Urol       Date:  2016-01-19       Impact factor: 20.096

8.  Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Authors:  Frederik L Giesel; Leon Will; Claudia Kesch; Martin Freitag; Christophe Kremer; Jonas Merkle; Oliver C Neels; Jens Cardinale; Boris Hadaschik; Markus Hohenfellner; Klaus Kopka; Uwe Haberkorn; Clemens Kratochwil
Journal:  J Nucl Med       Date:  2018-02-01       Impact factor: 10.057

9.  Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.

Authors:  Tobias Maurer; Gregor Weirich; Margret Schottelius; Martina Weineisen; Benjamin Frisch; Asli Okur; Hubert Kübler; Mark Thalgott; Nassir Navab; Markus Schwaiger; Hans-Jürgen Wester; Jürgen E Gschwend; Matthias Eiber
Journal:  Eur Urol       Date:  2015-05-06       Impact factor: 20.096

10.  Performance evaluation of Cerenkov luminescence imaging: a comparison of 68Ga with 18F.

Authors:  J Olde Heuvel; B J de Wit-van der Veen; K N Vyas; D S Tuch; M R Grootendorst; M P M Stokkel; C H Slump
Journal:  EJNMMI Phys       Date:  2019-10-24
View more
  5 in total

1.  Cerenkov Luminescence Imaging in Prostate Cancer: Not the Only Light That Shines.

Authors:  Judith Olde Heuvel; Berlinda J de Wit-van der Veen; Henk G van der Poel; Pim J van Leeuwen; Elise M Bekers; Maarten R Grootendorst; Kunal N Vyas; Cornelis H Slump; Marcel P M Stokkel
Journal:  J Nucl Med       Date:  2021-04-30       Impact factor: 11.082

2.  Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging-utilization of a short-pass filter to reduce technical pitfalls.

Authors:  Boris Alexander Hadaschik; Stephan Tschirdewahn; Christopher Darr; Pedro Fragoso Costa; Claudia Kesch; Ulrich Krafft; Lukas Püllen; Nina Natascha Harke; Jochen Hess; Tibor Szarvas; Johannes Haubold; Henning Reis; Wolfgang Peter Fendler; Ken Herrmann; Jan Philipp Radtke
Journal:  Transl Androl Urol       Date:  2021-10

3.  Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location.

Authors:  Magdalena Skubal; Benedict Mc Larney; Pamela Causa-Andrieu; Edwin C Pratt; Sudeep Das; Peter Sawan; Abdallah Araji; Christopher Riedl; Kunal Vyas; David Tuch; Jan Grimm
Journal:  Nat Biomed Eng       Date:  2022-04-11       Impact factor: 29.234

Review 4.  How molecular imaging will enable robotic precision surgery : The role of artificial intelligence, augmented reality, and navigation.

Authors:  Thomas Wendler; Fijs W B van Leeuwen; Nassir Navab; Matthias N van Oosterom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-29       Impact factor: 9.236

Review 5.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.